This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Roche Holding Yönetim
Yönetim kriter kontrolleri 2/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Thomas Schinecker
İcra Kurulu Başkanı
n/a
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | 3yrs |
| CEO sahipliği | 0.0004% |
| Yönetim ortalama görev süresi | 6yrs |
| Yönetim Kurulu ortalama görev süresi | 6yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Mar 21
ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential
Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
Anlatı Güncellemesi • Mar 07
ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside
The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.Anlatı Güncellemesi • Feb 21
ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead
Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
Anlatı Güncellemesi • Feb 07
ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating
Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.Analiz Makalesi • Feb 03
Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
Yeni Anlatı • Feb 01
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.Anlatı Güncellemesi • Jan 23
ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating
Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.Anlatı Güncellemesi • Jan 09
ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution
Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.Anlatı Güncellemesi • Dec 17
ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead
Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.Anlatı Güncellemesi • Dec 03
ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead
Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.Anlatı Güncellemesi • Nov 19
ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead
Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.Analiz Makalesi • Aug 20
Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...Yeni Anlatı • Feb 04
Roche Holding will see a 4.2576% revenue growth shaking the market
### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
Yeni Anlatı • Feb 02
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | CHF 13b |
| Sep 30 2025 | n/a | n/a | CHF 11b |
| Jun 30 2025 | n/a | n/a | CHF 9b |
| Mar 31 2025 | n/a | n/a | CHF 9b |
| Dec 31 2024 | n/a | n/a | CHF 8b |
| Sep 30 2024 | n/a | n/a | CHF 9b |
| Jun 30 2024 | n/a | n/a | CHF 11b |
| Mar 31 2024 | n/a | n/a | CHF 11b |
| Dec 31 2023 | n/a | n/a | CHF 11b |
| Sep 30 2023 | n/a | n/a | CHF 11b |
| Jun 30 2023 | n/a | n/a | CHF 11b |
| Mar 31 2023 | n/a | n/a | CHF 12b |
| Dec 31 2022 | CHF 5m | CHF 1m | CHF 12b |
| Sep 30 2022 | n/a | n/a | CHF 14b |
| Jun 30 2022 | n/a | n/a | CHF 15b |
| Mar 31 2022 | n/a | n/a | CHF 14b |
| Dec 31 2021 | CHF 4m | CHF 1m | CHF 14b |
| Sep 30 2021 | n/a | n/a | CHF 14b |
| Jun 30 2021 | n/a | n/a | CHF 14b |
| Mar 31 2021 | n/a | n/a | CHF 14b |
| Dec 31 2020 | CHF 4m | CHF 879k | CHF 14b |
| Sep 30 2020 | n/a | n/a | CHF 14b |
| Jun 30 2020 | n/a | n/a | CHF 13b |
| Mar 31 2020 | n/a | n/a | CHF 13b |
| Dec 31 2019 | CHF 2m | CHF 609k | CHF 13b |
Tazminat ve Piyasa: Thomas şirketinin toplam tazminatının Swiss pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.
Tazminat ve Kazançlar: Thomas 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Thomas Schinecker (50 yo)
3yrs
Görev süresi
CHF 5,335,592
Tazminat
Dr. Thomas Schinecker is Chairman of the Board of Roche Holdings, Inc. from March 14, 2023. Dr. Schinecker is Director since March 27, 2025 at Chugai Pharmaceutical Co., Ltd. He serves as Chairman of the B...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 13yrs | CHF 11.48m | 0.045% CHF 115.3m | |
| Group Chief Executive Officer | 3yrs | CHF 5.34m | 0.00045% CHF 1.2m | |
| Chief Financial Officer | 14.9yrs | CHF 6.05m | 0.0066% CHF 17.1m | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| General Counsel | 5.9yrs | Veri yok | Veri yok | |
| Chief Compliance Officer | 6.2yrs | Veri yok | Veri yok | |
| Head of Group Communications | less than a year | Veri yok | Veri yok | |
| Chief People Officer | 10yrs | CHF 4.25m | 0.0022% CHF 5.6m | |
| Head of Group Media Relations | no data | Veri yok | Veri yok | |
| Head of Corporate Business Development | no data | Veri yok | Veri yok | |
| Senior Vice President of Immunology | no data | Veri yok | Veri yok | |
| Global Head of Ophthalmology Roche pRED | no data | Veri yok | Veri yok |
6.0yrs
Ortalama Görev Süresi
55.5yo
Ortalama Yaş
Deneyimli Yönetim: ROG 'un yönetim ekibi deneyimli ve deneyimlidir ( 6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 13yrs | CHF 11.48m | 0.045% CHF 115.3m | |
| Director | 3yrs | Veri yok | 0.00063% CHF 1.6m | |
| Independent Vice Chairman | 30.2yrs | CHF 400.00k | 3.54% CHF 9.1b | |
| Independent Non Executive Director | 6yrs | CHF 360.00k | 0.00050% CHF 1.3m | |
| Non-Executive Independent Director | 11.2yrs | CHF 346.71k | 0% CHF 0 | |
| Non-Executive Independent Director | 9yrs | CHF 336.16k | 0.00059% CHF 1.5m | |
| Director | no data | Veri yok | Veri yok | |
| Non-Executive Independent Director | 6yrs | CHF 394.67k | Veri yok | |
| Director | 3yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 4yrs | CHF 272.50k | Veri yok |
6.0yrs
Ortalama Görev Süresi
57.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ROG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/03/16 06:24 |
| Gün Sonu Hisse Fiyatı | 2026/03/16 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Roche Holding AG 44 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Mark Purcell | Barclays |